Clinical Trials Browser

Advanced Gastric Cancer

Cholangiocarcinoma

Gastrointestinal Stromal Tumors

Salivary Gland Neoplasms

Osteosarcoma

Gastric Adenocarcinoma

Ovarian Neoplasms

Stomach Neoplasms

Carcinoma, Non-Small-Cell Lung

Ovarian Neoplasms

Advanced Biliary Tract Carcinoma

Neuroblastoma

Gestational Trophoblastic Disease

Advanced Primary Liver Cancer

Adenocarcinoma

Advanced Gastric Cancer

Breast Neoplasms

Adenocarcinoma

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Stomach Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Stomach Neoplasms

Stomach Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Esophageal Squamous Cell Carcinoma

Carcinoma, Hepatocellular

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Esophageal Squamous Cell Carcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Stomach Neoplasms

Malignant Neoplasms of Digestive Organs

Breast Neoplasms, Triple Negative Breast Neoplasms

Biliary Tract Neoplasms

Liver Neoplasms

Fludzoparib" and Anti-angiogenic

Squamous Cell Carcinoma of Head and Neck

Radioactive Iodine-refractory Differentiated Thyroid Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung

Colonic Neoplasms

Pancreatic Neoplasms, Stomach Neoplasms

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

Small Cell Lung Cancer Extensive Stage

Clinical Trials

PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

FAD-HCC-001

Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study

SOP-XH-IRB

SHR-2554

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Cocktail-001

SPARE-02

Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

ACADEMY

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

FASCINATE-N

A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer

TASK-05

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

ICT-HCC

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

Neoadjuvant Therapy for Locally Advanced Colon Cancer

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer